Filtered By:
Drug: Rituxan

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 93 results found since Jan 2013.

Case of Anti–Single Recognition Particle–Mediated Necrotizing Myopathy After Influenza Vaccination
We reported a 28-year-old healthy woman presented with subacute onset ascending muscle weakness 2 weeks after an annual influenza vaccination. Cerebral Spinal Fluid study showed normal cell counts with elevated protein and nerve conduction study showed reduced diffuse compound muscle action potential amplitudes suggesting a diagnosis of Guillain–Barré syndrome. Despite treatment using intravenous immunoglobulin, her condition continued to get worse with new bulbar and respiratory muscle weakness. Eventually, the diagnosis of anti–single recognition particle–mediated necrotizing myopathy was made based on elevated cr...
Source: Journal of Clinical Neuromuscular Disease - May 26, 2018 Category: Neurology Tags: Case Review Source Type: research

Successful treatment of antisynthetase syndrome presenting as rhabdomyolysis with rituximab
In this report, we present a patient who presented with features of rhabdomyolysis and was diagnosed with antisynthetase syndrome. This patient was treated with systemic steroids with partial improvement, foll owed by rituximab, which led to significant improvement in his condition. In addition, we summarize all cases reported in the literature of inflammatory myopathy-associated rhabdomyolysis.
Source: Rheumatology International - April 11, 2018 Category: Rheumatology Source Type: research

Management of Interstitial Lung Disease in Patients With Myositis Specific Autoantibodies
AbstractPurpose of ReviewTo review advances in the management of idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-associated ILD) in the past 5  years, with highlights in myositis-specific antibody (MSA) groups.Recent FindingsWith the recent advent of widespread MSA testing, the study of specific homogeneous autoantibody-based subgroups of IIM-associated ILD is now possible. The prevalence, severity, prognosis, and response to treatment are under study for these individual MSAs. Early evidence suggests that PL-7- and PL-12-positive patients are more likely to have ILD and worse severity, compared...
Source: Current Rheumatology Reports - April 10, 2018 Category: Rheumatology Source Type: research

Immune-Mediated Necrotizing Myopathy
AbstractPurpose of ReviewImmune-mediated necrotizing myopathy (IMNM) is a type of autoimmune myopathy characterized by relatively severe proximal weakness, myofiber necrosis with minimal inflammatory cell infiltrate on muscle biopsy, and infrequent extra-muscular involvement. Here, we will review the characteristics of patients with IMNM.Recent FindingsAnti-signal recognition particle (SRP) and anti-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies are closely associated with IMNM and define unique subtypes of patients. Importantly, the new European Neuromuscular Centre criteria recognize anti-SRP myopathy, ant...
Source: Current Rheumatology Reports - March 26, 2018 Category: Rheumatology Source Type: research

Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review
AbstractDermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by the presence of skin lesions and inflammation of skeletal muscles; however, this feature may be absent in amyopathic DM. DM is a rare disease, occurring at any age, and has two peaks of incidence: one in childhood between 5 and 15  years of age and one in adulthood between 40 and 60 years, with a female preponderance. DM has been associated with malignancy; therefore, every newly diagnosed patient should undergo screening investigations, but evidence-based guidelines on their extension are lacking. The etiopathogenesis is s till unclear,...
Source: Clinical Reviews in Allergy and Immunology - October 31, 2017 Category: Allergy & Immunology Source Type: research

Subacute myopathy as the initial presentation of anca positive vasculitis associated with crohns disease
Conclusions Vasculitis should be considered as a differential diagnosis for subacute myopathy in patients with an inflammatory or autoimmune phenotype. Muscle biopsy and ANCA immunofluorescence and titres are useful investigations. Whilst there is a lack of established evidence about the ideal agent for treating Crohn’s associated vasculitis, case reports suggest using TNF-alpha inhibitors or rituximab.
Source: Journal of Neurology, Neurosurgery and Psychiatry - May 8, 2017 Category: Neurosurgery Authors: Nham, B., Pamphlett, R., Keat, K., Patel, V. Tags: Abstracts Source Type: research

Mitochondrial Skeletal and Cardiac Myopathy Responsive to Aggressive Immunosuppression in Rapidly Progressing Systemic Sclerosis (P5.077)
Conclusions:Perivascular epimysial inflammation is rarely seen in any disease. Mitochondrial myopathy without myositis has not been reported in systemic sclerosis. We propose that ischemia caused by vasculopathy and fibrosis in systemic sclerosis, together with subclinical mitochondrial pathology, severely affected skeletal and cardiac muscle due to their high metabolic demands. An unusual presentation of myopathy in autoimmune disease suggests an underlying latent pathology, such as mitochondrial myopathy. Rapidly progressing autoimmune disease necessitates aggressive immunosuppression.Disclosure: Dr. Yeo has nothing to d...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Yeo, C., Bunin, V., Jovan, P., Cykowski, M., Smith, R. Tags: Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session Source Type: research

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
This study is registered with ClinicalTrials.gov, number NCT00784589. Findings Between May 10, 2010, and Dec 7, 2012, we enrolled 91 patients and randomly assigned 90 to treatment (90 were analysed; 1 patient withdrew consent before the random assignment). At month 24, 41 (89%) of 46 patients assigned to rituximab plus short-term prednisone were in complete remission off-therapy versus 15 (34%) of 44 assigned to prednisone alone (absolute difference 55 percentage points, 95% CI 38·4–71·7; p<0·0001. This difference corresponded to a relative risk of success of 2·61 (95% CI 1·71–3·99, p<0·0001), corr...
Source: The Lancet - March 23, 2017 Category: Journals (General) Source Type: research

Necrotising myopathy associated with anti-signal recognition particle (anti-SRP) antibody.
CONCLUSIONS: Unlike the cases described in the literature, there was a high frequency of extra-muscular symptoms in the patients studied. Moreover, one fifth of patients had previous exposure to statin use. There was a high relapse rates, but with good clinical and laboratory recovery, especially with pulse therapy regimen of methylprednisolone and/or IVIg. PMID: 28281460 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - March 12, 2017 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research

Subcutaneous immunoglobulins for the treatment of a patient with antisynthetase syndrome and secondary chronic immunodeficiency after anti-CD20 treatment: a case report
ConclusionsTaken together, these observations suggest that administration of immunoglobulin subcutaneously may be a useful therapeutic approach to tackle steroid-refractory antisynthetase syndrome while ensuring minimal side effects and improved treatment compliance. This treatment also allowed, in our case, for the regression of the chronic immunodeficiency secondary to rituximab treatment.
Source: Journal of Medical Case Reports - March 3, 2017 Category: Journals (General) Source Type: research

What's in the Literature?
Abstract: In this edition, we focus on neuromuscular junction disorders and myopathy. The newly published international consensus guidelines for the management of myasthenia gravis are reviewed. In addition, various emerging treatment options for myasthenia, including the use of methotrexate, rituximab, subcutaneous immunoglobulin, and thymectomy, are discussed. Recent studies examining the clinical and genetic features of several forms of congenital myasthenia gravis are also highlighted. The clinical features and treatment of late-onset Pompe disease are reviewed, as are studies in facioscapulohumeral dystrophy, idiopath...
Source: Journal of Clinical Neuromuscular Disease - November 22, 2016 Category: Neurology Tags: Literature Review Source Type: research

IgG4-related disease causing facial nerve and optic nerve palsies: Case report and literature review
We report a rare care of a 61-year-old female with IgG4-RD presenting as synchronous lesions of the middle ear and middle cranial fossa with polyneuropathy of cranial nerves II, VI, and VII. Initial histopathological evaluation of her resected ear mass suggested a benign inflammatory process but no specific diagnosis. Her symptoms progressed over 10months prompting re-evaluation of the specimen and consideration of the IgG4-RD diagnosis. Key pathologic features included prominent lymphoplasmacytic population, storiform fibrosis, obliterative phlebitis, and IgG4 specific staining. The patient was treated with high-dose intr...
Source: American Journal of Otolaryngology - September 26, 2016 Category: Endocrinology Source Type: research

Rituximab for the treatment of anti-HMGCR necrotizing autoimmune myopathy
The effectiveness of rituximab in refractory myositis has been suggested by case reports and case series. Recently, anti-HMGCR, a new autoantibody associated with necrotizing autoimmune myopathy and related to statin exposure was discovered. Our objective was to address the effectiveness of rituximab in the subgroup of anti-HMGCR necrotizing autoimmune myopathy. We identified 4 patients with anti-HMGCR necrotizing autoimmune myopathy that were treated with rituximab. Medical records were reviewed to assess their clinical presentation, muscle testing, serum CK levels, corticosteroid doses and associated immunosuppressant ag...
Source: Neuromuscular Disorders - September 10, 2016 Category: Neurology Authors: O. Landon-Cardinal, Y. Allenbach, A. Rigolet, A. Simon, N. Champtiaux, O. Benveniste Source Type: research

Treatment and outcomes in necrotising autoimmune myopathy: an australian perspective
• NAM is related to SRP and HMGCR antibodies, connective tissue disease and cancer.• NAM is responsive to immunotherapy, but often requires three or more agents.• IVIG and Rituximab are often effective, and can be used as steroid-sparing agents.• MHC-II and MAC staining on muscle biopsy may be markers of more refractory disease.
Source: Neuromuscular Disorders - September 1, 2016 Category: Neurology Authors: Catherine Ashton, Reimar Junckerstorff, Chris Bundell, Peter Hollingsworth, Merrilee Needham Source Type: research

Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle
Conclusions: Younger age at onset is associated with more severe weakness in anti‐SRP myositis. Furthermore, even among anti‐SRP patients whose strength improved with immunosuppression, most had ongoing disease activity as demonstrated by elevated CK levels. Finally, anti‐SRP patients were significantly weaker than anti‐HMGCR patients, providing evidence that these autoantibodies are associated with distinct forms of IMNM. This article is protected by copyright. All rights reserved.
Source: Arthritis Care and Research - April 24, 2016 Category: Rheumatology Authors: Iago Pinal‐Fernandez, Cassie Parks, Jessie L. Werner, Jemyma Albayda, Julie Paik, Sonye Danoff, Livia A. Casciola‐Rosen, Lisa Christopher‐Stine, Andrew L. Mammen Tags: Original Article Source Type: research